{"totalResults":4015,"results":[{"description":"Most ovarian tumors in children are not cancer. Treatment options include surgery, radiation therapy, chemotherapy, high-dose chemotherapy with stem cell transplant, and targeted therapy. Learn more about the risk factors, signs and symptoms, tests to diagnose, and treatment of childhood ovarian cancer in this expert-reviewed summary.","title":"Childhood Ovarian Cancer Treatment (PDQ®)\u2013Patient Version - National Cancer Institute","contentType":"pdqCancerInfoSummary","url":"https://www.cancer.gov/types/ovarian/patient/child-ovarian-treatment-pdq"},{"description":"NCI supports clinical trials studying new and more effective ways to detect and treat cancer. Find clinical trials for ovarian cancer.","title":"Ovarian Cancer Clinical Trials - National Cancer Institute","contentType":"nciAppModulePage","url":"https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/ovarian-cancer"},{"description":"Finding a way to detect endometrial and ovarian cancers early, when they are most likely to respond to treatment, has been a challenge for cancer researchers. An experimental liquid biopsy test called PapSEEK may help to change that, this Cancer Currents post explains.","title":"PapSEEK Test for Endometrial and Ovarian Cancer - National Cancer Institute","contentType":"cgvBlogPost","url":"https://www.cancer.gov/news-events/cancer-currents-blog/2018/liquid-biopsy-screening-test-endometrial-ovarian"},{"description":"The randomized, controlled Adjuvant Hormone Therapy trial was launched in 1990 to assess the effects of estrogen-alone hormone replacement therapy in women treated for epithelial ovarian cancer.","title":"Hormone Replacement Therapy for Ovarian Cancer - National Cancer Institute","contentType":"cgvArticle","url":"https://www.cancer.gov/types/ovarian/research/hrt-survival"},{"description":"Approximately 70 percent of women diagnosed with ovarian cancer will die from the disease. Read about the NCI-funded combination drug trial that has successfully treated Betsy Brauser's recurrent cancer.","title":"Combining Drugs to Treat Ovarian Cancer - National Cancer Institute","contentType":"cgvArticle","url":"https://www.cancer.gov/research/infrastructure/clinical-trials/betsy-brauser-combining-drugs-treat-ovarian-cancer"},{"description":"Use of intraperitoneal chemotherapy, along with intravenous chemotherapy, improves survival in some women with advanced ovarian cancer, but its use in clinical practice has been limited, according to a new study.","title":"IP Chemo for Ovarian Cancer is Underused - National Cancer Institute","contentType":"cgvBlogPost","url":"https://www.cancer.gov/news-events/cancer-currents-blog/2015/ip-chemo"},{"description":"This evidence-based, expert-reviewed summary discusses the clinical presentation, risk factors, histology, molecular features, prognosis, and treatment of pediatric ovarian cancer.","title":"Childhood Ovarian Cancer Treatment (PDQ®)\u2013Health Professional Version - National Cancer Institute","contentType":"pdqCancerInfoSummary","url":"https://www.cancer.gov/types/ovarian/hp/child-ovarian-treatment-pdq"},{"description":"Tomi is studying why women of different population groups are less likely to receive high-quality ovarian cancer treatment. Her NCI grant converted from an R01 to an R37 grant. Learn what that means for her research.","title":"Striving to Eliminate Ovarian Cancer Disparities - National Cancer Institute","contentType":"cgvArticle","url":"https://www.cancer.gov/research/areas/disparities/eliminate-ovarian-cancer-disparities"},{"description":"Women with newly diagnosed advanced ovarian cancer may benefit from initial treatment with one of several PARP inhibitors, according to results from three separate clinical trials. The studies tested the PARP inhibitors niraparib (Zejula), olaparib (Lynparza), and veliparib.","title":"PARP Inhibitors as Initial Treatment for Ovarian Cancer - National Cancer Institute","contentType":"cgvBlogPost","url":"https://www.cancer.gov/news-events/cancer-currents-blog/2019/parp-inhibitors-ovarian-cancer-initial-treatment"},{"description":"NCI-funded research helped identify inherited BRCA1 and BRCA2 genetic mutations and their connection to breast and ovarian cancer. From this research, a screening test was also developed to help patients make informed decisions about their health.","title":"Discovery \u2013 BRCA Connection to Breast and Ovarian Cancer - National Cancer Institute","contentType":"cgvArticle","url":"https://www.cancer.gov/research/progress/discovery/brca"}]}